Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 9/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 8/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29058360 | 0.93 | OPRL1 (0.40) | FEN1ALOX5APHTR2AHCRTR1HCRTR2 | |
| SCHEMBL3739617 | 0.81 | HTR2A (0.43) | FEN1ALOX5APHTR2AHCRTR1HCRTR2 | |
| SCHEMBL3749818 | 0.80 | HTR2A (0.42) | FEN1ALOX5APHTR2AHCRTR1HCRTR2 | |
| SCHEMBL11164464 | 0.79 | HCRTR1 (0.38) | FEN1ALOX5APHTR2AHCRTR1HCRTR2 | |
| SCHEMBL3747583 | 0.78 | FEN1 (0.43) | FEN1ALOX5APHTR2AHCRTR1HCRTR2 | |
| SCHEMBL2019967 | 0.77 | ADRA1A (0.46) | HCRTR2PDCD1CD274KMT2A | |
| SCHEMBL17202931 | 0.77 | HTR2A (0.40) | FEN1ALOX5APHTR2AHCRTR1HCRTR2 | |
| SCHEMBL16957749 | 0.77 | HTR2C (0.37) | FEN1ALOX5APHTR1AKMT2A | |
| SCHEMBL6736896 | 0.76 | POLB (0.47) | MAPT | |
| SCHEMBL17729508 | 0.76 | HTR2A (0.39) | FEN1ALOX5APHTR2AHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-07 | — | — | US | disclosed |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | GLRA1, AGXT, B4GALT1 | FEN1 4062/4885ALOX5AP 3346/4885HTR2A 1065/4885 |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | GLRA1, AGXT, B4GALT1 | FEN1 4062/4885ALOX5AP 3346/4885HTR2A 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.